XTX Topco Ltd Purchases Shares of 2,921 Charles River Laboratories International, Inc. (NYSE:CRL)

XTX Topco Ltd acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,921 shares of the medical research company’s stock, valued at approximately $539,000.

Several other large investors have also recently modified their holdings of the stock. Virtu Financial LLC purchased a new position in Charles River Laboratories International in the 3rd quarter worth approximately $601,000. JPMorgan Chase & Co. increased its stake in shares of Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after buying an additional 85,759 shares during the period. Veracity Capital LLC bought a new stake in Charles River Laboratories International during the 4th quarter valued at $589,000. Lord Abbett & CO. LLC boosted its position in Charles River Laboratories International by 5.8% during the 3rd quarter. Lord Abbett & CO. LLC now owns 108,715 shares of the medical research company’s stock valued at $21,413,000 after buying an additional 5,959 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its holdings in Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock worth $330,231,000 after acquiring an additional 47,221 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CRL shares. Mizuho dropped their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating for the company in a report on Wednesday, April 9th. Robert W. Baird cut their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. The Goldman Sachs Group cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and reduced their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Barclays cut their price target on shares of Charles River Laboratories International from $160.00 to $145.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $182.00.

Charles River Laboratories International Stock Up 1.6 %

Shares of NYSE:CRL opened at $105.89 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The stock has a market capitalization of $5.20 billion, a price-to-earnings ratio of 705.91, a PEG ratio of 4.54 and a beta of 1.45. The stock has a fifty day simple moving average of $151.07 and a two-hundred day simple moving average of $173.87. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.46 EPS. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).